Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 26

Sort by

Sort Order Select

Journal Articles

Do Changes in Transplant Practice Influence Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic Cell Transplantation (aHCT) for Non-Hodgkin Lymphoma (NHL)?

Can-Lan Sun, Jennifer Berano-Teh, Patrick Halliday, Lindsey Hageman, Maya Ramamurthy, Saro Armenian, Alicia Gonzales, Liezl Atencio, Liton Francisco, F. Lennie Wong, Auayporn Nademanee, MD, Robert W Chen, MD, Margaret O'Donnell, Joseph Rosenthal, Leslie L. Popplewell, MD, Shirong Wang, Stephen J. Forman, Ravi Bhatia, Smita Bhatia, PhD

Blood (2014) 124 (21): 430.

https://doi.org/10.1182/blood.V124.21.430.430

Published: 2014

Journal Articles

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Zheng Zhou, MD PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Allison Crosby-Thompson, Ann Vanderplas, MS, Gregory A Abel, MD MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark Kaminski, Myron S. Czuczman, MD, Michael M. Millenson, MD, Joyce Niland, PhD, Andrew D. Zelenetz, MD PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2014) 124 (21): 3046.

https://doi.org/10.1182/blood.V124.21.3046.3046

Published: 2014

Journal Articles

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Ryotaro Nakamura, Robert Chen, MD, Joycelynne Palmer, PhD, Karl Gaal, MD, Auayporn Nademanee, MD, Leslie Popplewell, MD, James E. Talmadge, PhD, Stephen Gillies, PhD, David Colcher, PhD, Stephen J. Forman, MD, Andrew Raubitschek, MD

Blood (2013) 122 (21): 1808.

https://doi.org/10.1182/blood.V122.21.1808.1808

Published: 2013

Journal Articles

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Robert Chen, MD, Paul Frankel, PhD, Leslie Popplewell, MD, Tanya Siddiqi, MD, Wei Ye, Joel Conrad, BS, Michelle Mott, RN, Auayporn Nademanee, MD, Myo Htut, MD, Stephen J. Forman, MD, Mark Kirschbaum, MD

Blood (2013) 122 (21): 4398.

https://doi.org/10.1182/blood.V122.21.4398.4398

Published: 2013

Journal Articles

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

Robert Chen, MD, Joycelynne Palmer, PhD, Ni-Chun Tsai, MS MPH, Sandra H. Thomas, PhD, Tanya Paris, Leslie Popplewell, MD, Chatchada Karanes, MD, Tanya Siddiqi, MD, Auayporn Nademanee, MD, Ji-Lian Cai, MD, Stephen J. Forman, MD

Blood (2013) 122 (21): 3374.

https://doi.org/10.1182/blood.V122.21.3374.3374

Published: 2013

Journal Articles

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Zheng Zhou, MD, PhD, Alfred W. Rademaker, PhD, Leo I. Gordon, MD, Ann S. LaCasce, MD, Ann Vanderplas, MS, Allison Crosby-Thompson, Andrew D Zelenetz, MD, PhD, Gregory A. Abel, MD, MPH, Maria A. Rodriguez, MD, Auayporn Nademanee, MD, Mark S. Kaminski, MD, Myron S. Czuczman, MD, Michael Millenson, MD, Joyce Niland, PhD, Jonathan W. Friedberg, MD, Jane N. Winter, MD

Blood (2012) 120 (21): 2656.

https://doi.org/10.1182/blood.V120.21.2656.2656

Published: 2012

Journal Articles

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Makiko Ban-Hoefen, MD, Ann Vanderplas, MS, Jennifer L. Kelly, PhD, MPH, Allison Crosby-Thompson, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Joyce Niland, PhD, Ann LaCasce, MD, Jonathan W. Friedberg, MD

Blood (2012) 120 (21): 2669.

https://doi.org/10.1182/blood.V120.21.2669.2669

Published: 2012

Journal Articles

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

Alex F Herrera, MD, Allison Crosby-Thompson, Jonathan W. Friedberg, MD, Gregory A. Abel, MD, MPH, Myron S. Czuczman, MD, Leo I. Gordon, MD, Mark S. Kaminski, MD, Michael Millenson, MD, Auayporn Nademanee, MD, Joyce Niland, PhD, Maria A. Rodriguez, MD, Andrew D. Zelenetz, MD, PhD, Ann S. LaCasce, MD

Blood (2012) 120 (21): 1610.

https://doi.org/10.1182/blood.V120.21.1610.1610

Published: 2012

Journal Articles

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

Robert W. Chen, MD, Leslie Popplewell, MD, Paul Frankel, PhD, Tanya Siddiqi, MD, Joel Conrad, BS, Michelle Mott, RN, Myo Htut, MD, Auayporn Nademanee, MD, Stephen J Forman, MD, Mark Kirschbaum, MD

Blood (2012) 120 (21): 3698.

https://doi.org/10.1182/blood.V120.21.3698.3698

Published: 2012

Journal Articles

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Frederick L Locke, MD, Joseph Pidala, MD, MS, Barry Storer, PhD, Paul J. Martin, MD, Michael A Pulsipher, MD, Thomas Chauncey, MD, PhD, Niels Jacobsen, MD, DMSC, Nikolaus Kroeger, MD, Irwin Walker, MBBS, Mary C Territo, Susan Light, MD, Ginna G Laport, MD, Auayporn Nademanee, MD, Raymond Powles, MD, Armand Keating, MD, Gerard Socie, MD, Claudio Anasetti, MD

Blood (2012) 120 (21): 4195.

https://doi.org/10.1182/blood.V120.21.4195.4195

Published: 2012

Journal Articles

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

Auayporn Nademanee, MD, Andrew Raubitschek, MD, Arturo Molina, MD, Joycelynne Palmer, Ph.D, Ni-Chun Tsai, MS, Amrita Krishnan, MD, Neil Kogut, MD, Stephen Forman, MD

Blood (2007) 110 (11): 1891.

https://doi.org/10.1182/blood.V110.11.1891.1891

Published: 2007

Journal Articles

High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.

Mukta Arora, MD, MS, Stephen Spellman, MBS, Michael Haagenson, MS, John P. Klein, PhD, Carolyn Hurley, PhD, George Selby, MD, Joseph Antin, MD, Nancy Kernan, MD, Craig Kollman, PhD, Auayporn Nademanee, MD, Daniel J. Weisdorf, MD, Mary M. Horowitz, MD, MS, Philip McGlave, MD, Effie Petersdorf, MD

Blood (2007) 110 (11): 171.

https://doi.org/10.1182/blood.V110.11.171.171

Published: 2007

Journal Articles

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

Joseph Rosenthal, MD, Jeffrey Wong, MD, Anthony Stein, MD, Ellen Bolotin, MD, PhD, Chatchada Karanes, MD, Leslie Popplwell, MD, Auayporn Nademanee, MD, Firoozeh Sahebi, MD, Margaret O’Donnell, MD, Maria Delioukina, MD, George Somlo, MD, Anna Pawlowska, MD, Debbie Hitt, RN, Marianna Shakhnovits, MD, Stephen Forman, MD

Blood (2007) 110 (11): 3021.

https://doi.org/10.1182/blood.V110.11.3021.3021

Published: 2007

Journal Articles

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

Amrita Y. Krishnan, MD, Joycelynne M. Palmer, PhD, Smita C. Bhatia, MD, MPH, Auayporn Nademanee, MD, Stephen J. Forman, MD, Andrew Raubitschek, MD, Arturo M. Molina, MD, Henry Fung, MD, Peter Falk, MD, Marilyn J. Slovak, MD, Nicole Tsai, MS, Jennifer Simpson, BA, Ravi Bhatia, MD

Blood (2007) 110 (11): 1082.

https://doi.org/10.1182/blood.V110.11.1082.1082

Published: 2007

Journal Articles

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

Ryotaro Nakamura, MD, Roberto Rodriguez, MD, Auayporn Nademanee, MD, Joycelynne Palmer, PhD, David Senitzer, PhD, David Snyder, MD, Jasmine Zain, MD, Vinod Pullarkat, MD, Stephen J. Forman, MD, Pablo Miguel Parker, MD

Blood (2006) 108 (11): 2866.

https://doi.org/10.1182/blood.V108.11.2866.2866

Published: 2006

Journal Articles

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

George Somlo, MD, Dajun Qian, PhD, Firoozeh Sahebi, MD, Neil Martin Kogut, MD, Roberto Rodriguez, MD, Pablo Miguel Parker, MD, Leslie Popplewell, MD, Amrita Krishnan, MD, Joycelynne Palmer, PhD, Anthony Selwyn Stein, MD, Ricardo Spielberger, MD, Jeffrey Schriber, MD, Joseph Alvarnas, MD, Warren Chow, MD, Auayporn Nademanee, MD, Jasmine M. Zain, MD, Margaret R. O’Donnell, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3089.

https://doi.org/10.1182/blood.V108.11.3089.3089

Published: 2006

Journal Articles

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Amrita Y. Krishnan, MD, Auayporn Nademanee, MD, Andrew Raubitschek, MD, Henry C. Fung, MD, Arturo Molina, MD, David Yamauchi, MD, Peter M. Falk, MD, Ricardo Spielberger, MD, Joycelynne Palmer, PhD, Ni Chun Tsai, MS, MPH, Jeffrey Schriber, MD, Stephen J. Forman, MD

Blood (2006) 108 (11): 3043.

https://doi.org/10.1182/blood.V108.11.3043.3043

Published: 2006

Journal Articles

Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Umbilical Cord Blood Units (UCB) That Were Depleted of Plasma, but Not of Red Blood Cells.

Robert Chow, MD, AM, Tang-Her Jaing, MD, David Gjertson, MD, Joseph Rosenthal, MD, Auayporn Nademanee, MD, Chatchada Karanes, MD, Michael Graham, MD, Patrick Tan, MD, Lawrence D. Petz, MD

Blood (2005) 106 (11): 5459.

https://doi.org/10.1182/blood.V106.11.5459.5459

Published: 2005

Journal Articles

Clinical Outcome of Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells Prior to Cryopreservation.

Robert Chow, MD, AM, David Gjertson, PhD, Joseph Rosenthal, MD, Auayporn Nademanee, MD, Chatchada Karanes, MD, Tang-Her Jaing, MD, Michael Graham, MD, Patrick Tan, MD, Lawrence D. Petz, MD

Blood (2005) 106 (11): 2045.

https://doi.org/10.1182/blood.V106.11.2045.2045

Published: 2005

Journal Articles

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Ryotaro Nakamura, MD, Joycelynne Palmer, PhD, Roberto Rodriguez, MD, Pablo Parker, MD, David Senitzer, PhD, Anthony Stein, MD, Josheph Rosenthal, MD, Sean Wang, MD, Jeffrey Schriber, MD, Stephen J. Forman, MD, Auayporn Nademanee, MD

Blood (2005) 106 (11): 2056.

https://doi.org/10.1182/blood.V106.11.2056.2056

Published: 2005

NARROW

Do Changes in Transplant Practice Influence Risk of Therapy-Related Myelodysplasia/ Acute Myeloid Leukemia after Autologous Hematopoietic Cell Transplantation (aHCT) for Non-Hodgkin Lymphoma (NHL)?

High Body Mass Index (BMI) in North American Elderly Diffuse Large B-Cell Lymphoma (DLBCL) Patients Treated with Rituximab (R)-CHOP Compensates for Negative Impact of Male Gender

Immunologic and Clinical Responses To a CD20-Targeted Immunocytokine, DI-Leu16-IL2, In Relapsed Non-Hodgkin Lymphoma

Final Results Of A Phase 2 Study Of Vorinostat Plus Rituximab In Newly Diagnosed, Relapsed Or Refractory Indolent Non-Hodgkin's Lymphoma

Brentuximab Vedotin Improves HCT-CI, CR Status, and Peri-Transplant Toxicity In Patients With Relapsed/Refractory Hodgkin Lymphoma Heading To RIC Allo-HCT

An Enhanced International Prognostic Index (IPI) for Patients with Diffuse Large B-Cell Lymphoma (DLBCL) in the Rituximab Era Using the National Comprehensive Cancer Network (NCCN) Database.

Natural History of Transformed Non-Hodgkin Lymphoma in the Rituximab Era: Analysis of the National Comprehensive Cancer Network (NCCN) NHL Outcomes Database.

Comparison of Referring and Final Pathology for T-Cell Lymphomas in the NCCN

A Phase 2 Study of Vorinostat (Suberoylanilide Hydroxamic Acid, SAHA) Plus Rituximab in Newly Diagnosed, Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

The Anti-CD25 Antibody Daclizumab Delays Treg Reconstitution, Promotes CD4 Memory, and Does Not Prevent Acute or Chronic Gvhd After Allogeneic Stem Cell Transplantation

Updated Results of High-Dose Yttrium 90 ( 90 Y) Ibritumomab Tiuxetan with High-Dose Etoposide (VP-16) and Cyclophosphamide (CY) Followed by Autologous Hematopoietic Cell Transplant (AHSCT) for Poor-Risk or Refractory B-Cell Non-Hodgkin’s Lymphoma.

High Resolution HLA Matched Unrelated Donor Versus HLA Identical Sibling Transplantation for Chronic Phase CML.

Augmenting the Reduced Intensity Conditioning (RIC) Regimen of Fludarabine (FLU) and Melphalan (MEL) by Addition of Total Marrow and Lymph Node Irradiation (TMLI) Using Helical Tomotherapy in Patients (pts) with Advanced Hematological Malignancies.

The Impact of Incorporating Targeted Radioimmunotherapy (RIT) into Transplant Preparative Regimens on the Incidence of Therapy Related Myelodysplasia (t-MDS) or AML (t-AML) Following Autologous Stem Cell Transplant (ASCT) for Lymphoma.

The Use of Sirolimus Combined with Tacrolimus and Low-Dose Methotrexate Is Effective in Preventing Graft-Versus-Host Disease after Unrelated Donor Hematopoietic Stem Cell Transplantation.

Tandem Cycle High-Dose Melphalan and Busulfan/Cyclophosphamide Followed by Maintenance Interferon Alpha-2 (IF) with or without Thalidomide (Thal) Is Associated with High Complete and Very Good Partial Response Rates, Improved Progression-Free, and Overall Survival.

A Comparison of Beam and Yttrium 90 Ibritumomab Tiuxetan (Zevalin®) in Addition to Beam (Z-BEAM) in Older Patients Undergoing Autologous Stem Cell Transplant (ASCT) for B-Cell Lymphomas: Impact of Radioimmunotherapy on Transplant Outcomes.

Hematopoietic Stem Cell Transplantation (HSCT) for Benign Indications Using Umbilical Cord Blood Units (UCB) That Were Depleted of Plasma, but Not of Red Blood Cells.

Clinical Outcome of Hematopoietic Stem Cell Transplantation (HSCT) Using Plasma Depleted Umbilical Cord Blood Units (UCB) That Were Not Depleted of Red Blood Cells Prior to Cryopreservation.

Transplant CD34+ Cell Dose Affects Outcomes Following Allogeneic Peripheral Blood Stem Cell Transplantation from a Matched Unrelated Donor.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only